Endosomal gene expression: a new indicator for prostate cancer patient prognosis?
Authors
Johnson, Ian R DParkinson-Lawrence, Emma J
Keegan, Helen
Spillane, Cathy D
Barry-O'Crowley, Jacqui
Watson, William R
Selemidis, Stavros
Butler, Lisa M
O'Leary, John J
Brooks, Doug A
Issue Date
2015-11-10Keywords
PROSTATE CANCERGENETICS
MeSH
Adaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular Transport
Biomarkers, Tumor
Calcium-Binding Proteins
Cell Cycle Proteins
Cohort Studies
Disease Progression
Endosomal Sorting Complexes Required for Transport
Endosomes
Follow-Up Studies
Gene Expression Profiling
Humans
Male
NADPH Oxidase
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Recurrence, Local
Prognosis
Prostatic Intraepithelial Neoplasia
Prostatic Neoplasms
RNA, Messenger
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Survival Rate
Vesicular Transport Proteins
rab5 GTP-Binding Proteins
Metadata
Show full item recordCitation
Endosomal gene expression: a new indicator for prostate cancer patient prognosis? 2015, 6 (35):37919-29 OncotargetPublisher
Impact PublishersJournal
OncotargetDOI
10.18632/oncotarget.6114PubMed ID
26473288Abstract
Prostate cancer continues to be a major cause of morbidity and mortality in men, but a method for accurate prognosis in these patients is yet to be developed. The recent discovery of altered endosomal biogenesis in prostate cancer has identified a fundamental change in the cell biology of this cancer, which holds great promise for the identification of novel biomarkers that can predict disease outcomes. Here we have identified significantly altered expression of endosomal genes in prostate cancer compared to non-malignant tissue in mRNA microarrays and confirmed these findings by qRT-PCR on fresh-frozen tissue. Importantly, we identified endosomal gene expression patterns that were predictive of patient outcomes. Two endosomal tri-gene signatures were identified from a previously published microarray cohort and had a significant capacity to stratify patient outcomes. The expression of APPL1, RAB5A, EEA1, PDCD6IP, NOX4 and SORT1 were altered in malignant patient tissue, when compared to indolent and normal prostate tissue. These findings support the initiation of a case-control study using larger cohorts of prostate tissue, with documented patient outcomes, to determine if different combinations of these new biomarkers can accurately predict disease status and clinical progression in prostate cancer patients.Item Type
ArticleLanguage
enISSN
1949-2553ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.6114
Scopus Count
Collections
Related articles
- Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
- Authors: Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G
- Issue date: 2014 May
- Altered endosome biogenesis in prostate cancer has biomarker potential.
- Authors: Johnson IR, Parkinson-Lawrence EJ, Shandala T, Weigert R, Butler LM, Brooks DA
- Issue date: 2014 Dec
- Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
- Authors: Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann A, Heberer M, Spagnoli GC, Wyler S, Mengus C
- Issue date: 2013 Mar
- Asporin is a stromally expressed marker associated with prostate cancer progression.
- Authors: Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA
- Issue date: 2017 Mar 14
- RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
- Authors: Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY
- Issue date: 2014 Dec